Novartis, GBT sickle cell drugs face coverage hurdles as gene therapy threats loom: survey

Novartis’ Adakveo and Global Blood Therapeutics’ Oxbryta started their commercial life in 2019 as novel drugs for sickle cell disease. While physicians like their efficacy and safety profiles, formulary coverage is a hurdle, doctors told analysts in a survey. That's not to mention potential gene therapy threats.